

Financial news for PBMD dated on 2017-11-20: Prima BioMed is Now Immuteq Ltd; New Symbol is IMMP

Financial news for PBMD dated on 2017-10-11: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PBMD dated on 2017-09-08: Prima BioMed Granted Japanese Patent for IMP731 Antibody

Financial news for PBMD dated on 2017-09-05: Prima BioMed Granted Japanese Patent Grant for Lead Product IMP321 in Infectious Disease

Financial news for PBMD dated on 2017-08-16: Prima BioMed Receives AUD\$1.3M Tax Refund from French Government

Financial news for PBMD dated on 2017-07-16: Prima BioMed Announces Second Milestone Payment for IMP701 Program; Payment Amount from Novartis Not Disclosed

Financial news for PBMD dated on 2017-07-10: Prima BioMed Announces Approval for Initiation of 'INSIGHT' Clinical Trial in Germany

Financial news for PBMD dated on 2017-06-29: 6-K From Prima BioMed Shows Pricing Of \$5M Registered Direct Offering At \$1.90/ADS

Financial news for PBMD dated on 2017-06-26: Prima BioMed Gives an Update on Clinical Trials

Financial news for PBMD dated on 2017-06-26: Prima Biomed Says Clinical Studies of IMP321 are Progressing Well

Financial news for PBMD dated on 2017-06-04: Prima Biomed Announced LAG-3LG (IMP321) Demonstrates Positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial #ASCO17

Financial news for PBMD dated on 2017-05-31: Prima BioMed Announces Formation of Clinical Advisory Board to Serve as Resource for Development of IMP321

Financial news for PBMD dated on 2017-04-18: Prima Biomed Announced Approval Received to Commence 3rd Cohort of Phase I Clinical Trial for IMP321 In Combination With Keytruda

Financial news for PBMD dated on 2017-04-12: Prima BioMed Receives A\$492,144 Tax Refund from Australian Government to be Applied toward Furthering Clinical Trial Program for IMP321

Financial news for PBMD dated on 2017-03-15: Prima Biomed Completes Recruitment For Second Patient Cohort In Melanoma Trial

Financial news for PBMD dated on 2017-02-28: UPDATE: Prima BioMed Unit Immuteq Issued New Patent for IMP731 'Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response'

Financial news for PBMD dated on 2017-02-28: Prima BioMed Shares Spike Sharply, Now Up 30% for Session, as Traders Circulate US PTO Doc on Use of IMP731 Antibody

Financial news for PBMD dated on 2017-02-28: Traders Circulating USPTO Document Highlighting Prima Biomed's Subsidiary Immuteq Issued New Patent For IMP731 Antibody

Financial news for PBMD dated on 2017-02-12: Prima BioMed Receives ~A\$860K Tax Credit Payment from French Government -

Financial news for PBMD dated on 2017-01-20: Prima Biomed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer

Financial news for PBMD dated on 2017-01-18: Prima BioMed to Maintain NASDAQ Listing; ADS has Maintained a Closing Price of \$1.00/Share or Greater for 10 Consecutive Days

Financial news for PBMD dated on 2017-01-06: Prima Biomed Enters New Material Transfer Agreement With Japan's Cytlimic

Financial news for PBMD dated on 2017-01-02: Prima Biomed Announces New Product Candidate IMP761, LAG-3 Agonist Antibody

Financial news for PBMD dated on 2016-12-29: 12 Biggest Mid-Day Gainers For Thursday

Financial news for PBMD dated on 2016-12-29: Mid-Day Market Update: Prima BioMed Climbs Following Positive IMP321 Data; Interpace Diagnostics Shares Slide

Financial news for PBMD dated on 2016-12-29: Mid-Morning Market Update: Markets

Mostly Flat; Jobless Claims Drop To 265,000

Financial news for PBMD dated on 2016-12-29: Prima BioMed +28% @\$2.99 Following Positive IMP321 Data

Financial news for PBMD dated on 2016-12-29: 15 Stocks Moving In Thursday's Pre-Market Session

Financial news for PBMD dated on 2016-12-29: Prima BioMed Announces First Clinical Data from Combination of IMP321 With Keytruda Show No Safety Concerns

Financial news for PBMD dated on 2016-12-21: Prima BioMed Announces Data From IMP321 AIPAC Phase IIb Trial, Confirms Previous Results Showing Safety And Tolerability

Financial news for PBMD dated on 2016-12-19: Prima BioMed Receives UK Approval for AIPAC Study

Financial news for PBMD dated on 2016-12-18: Prima BioMed Announces ADR Ratio Change from 30 Ordinary Share to 100

Financial news for PBMD dated on 2016-11-22: WuXi Biologics, Prima Signs MOU; Announces Strategic Development and Manufacturing Partnership

Financial news for PBMD dated on 2016-10-13: Prima BioMed to Present at 2016 Society for Immunotherapy of Cancer Conference

Financial news for PBMD dated on 2016-08-24: European Patent Grants For IMP731 Antibody

Financial news for PBMD dated on 2016-08-18: Prima BioMed Reports A\$20M in Cash as of June 30, 2016; Says Cash Reach Extended into Q4 2017

Financial news for PBMD dated on 2016-08-10: Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency

Financial news for PBMD dated on 2016-07-28: Prima Biomed Reports A\$20.88M Cash at End of Q4 -6K

Financial news for PBMD dated on 2016-07-12: Prima BioMed Collaborates in Investigator Sponsored New Clinical Trial for IMP321 in Solid Tumors

Financial news for PBMD dated on 2016-06-21: Prima BioMed Announces First Safety, Pharmacokinetics, Immuno-Monitoring Data From Phase IIb Clinical Trial of IMP321 -

Financial news for PBMD dated on 2016-05-27: Prima Biomed Files for Up to \$60M ADS Offering -F3

Financial news for PBMD dated on 2016-05-13: Prima Biomed Chairman, CEO Issue Letter to Shareholders

Financial news for PBMD dated on 2016-05-12: Here's Why Prima BioMed Is Up 15%

Financial news for PBMD dated on 2016-05-12: Prima Biomed +27% Premarket @\$1.19 Following Announcement of Licensing Deal, Stake in Sydys

Financial news for PBMD dated on 2016-05-12: UPDATE: Prima Biomed to Receive 9.9% Equity Stake in Sydys; Could Receive A\$400M+ for Achievement of Sales Targets, Plus Royalties on Sales

Financial news for PBMD dated on 2016-05-12: Prima BioMed Enters Into Sale, Licensing Agreement With Sydys to Advance CVac Program

Financial news for PBMD dated on 2016-05-02: PrimaBioMed Jumps 10% As Company Receives Japanese Patent Grant

Financial news for PBMD dated on 2016-05-01: Prima Biomed Announces Japanese Patent Grants for IMP321 in Cancer

Financial news for PBMD dated on 2016-04-22: Prima Biomed Attributes Recent Trading in Shares to Positive Maxim Report -6K

Financial news for PBMD dated on 2016-04-20: Prima Biomed's Data From Partnership With Japans NEC & Yamaguchi University Shows Potential In Solid Cancer Vaccine, IMP321 Effective Adjuvant

Financial news for PBMD dated on 2016-04-18: Maxim Group Initiates Coverage on Prima Biomed at Buy, Announces \$4.00 PT

Financial news for PBMD dated on 2016-03-08: Tom Bloomfield Named Prima Biomed Joint

Company Secretary on Temporary Basis

Financial news for PBMD dated on 2016-03-04: Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency

Financial news for PBMD dated on 2016-03-02: Prima BioMed, WuXi Biologics Announce First Dose of Chinese-Manufactured Biologic in EU Clinical Trial

Financial news for PBMD dated on 2016-01-28: Prima BioMed Announces Granting of Patent Number US 9,244,059 Eentitled Cytotoxic Anti-LAG-3 Monoclonal Antibody and its Use in the Treatment or Prevention of Organ Transplant Rejection and Autoimmune Disease'

Financial news for PBMD dated on 2015-12-31: Prima BioMed Shares Rally Following New Buy Rating, \$6 Target From Roth Capital

Financial news for PBMD dated on 2015-12-31: Benzinga's Top #PreMarket Gainers

Financial news for PBMD dated on 2015-12-31: Prima Biomed +17.1% Premarket @\$1.30; Roth Initiated PBMD on Wednesday With Buy Rating, \$6 PT

Financial news for PBMD dated on 2015-12-30: UPDATE: Roth Capital Says Prima Is In Leading Position To Develope New Checkpoint Inhibition Pathways

Financial news for PBMD dated on 2015-12-30: Roth Capital Initiates Coverage on Prima Biomed at Buy, Announces \$6.00 PT

Financial news for PBMD dated on 2015-12-22: Prima BioMed Initiates Phase IIb Study in Metastatic Breast Cancer

Financial news for PBMD dated on 2015-12-11: Benzinga's Top #PreMarket Gainers

Financial news for PBMD dated on 2015-12-11: Prima Biomed +15% Premarket @\$1.38; Announced Progress in Collaboration With NEC Corporation and Yamaguchi University in Japan

Financial news for PBMD dated on 2015-12-11: Prima Biomed Announces Progress in Collaboration With NEC Corporation and Yamaguchi University in Japan

Financial news for PBMD dated on 2015-12-03: Morning Market Gainers

Financial news for PBMD dated on 2015-12-03: Benzinga's Top Initiations

Financial news for PBMD dated on 2015-12-03: Prima BioMed Shares Rally Following New Outperform Rating, \$6 Target At FBR

Financial news for PBMD dated on 2015-12-03: FBR Capital Initiates Coverage on Prima Biomed at Outperform, Announces \$6.00 PT

Financial news for PBMD dated on 2015-11-27: Prima Biomed Spikes Higher on Report of Tax Rebate in Australia

Financial news for PBMD dated on 2015-11-25: Prima Biomed +5.69% Premarket @\$1.30 Following Posting of Investor Presentation in 6K Filing on Tuesday

Financial news for PBMD dated on 2015-11-24: Prima Biomed +7.5% After-Hours Following Release of Investor Update in 6K

Financial news for PBMD dated on 2015-11-18: Prima BioMed ShowsPhase I Combination Study of IMP321 + Checkpoint Inhibitor

Financial news for PBMD dated on 2015-11-02: Morning Market Losers

Financial news for PBMD dated on 2015-10-30: Prima Biomed Announces A\$2M Investment from Institutional Investor to be Used to Fund Prima's IMP321 Clinical Trial Program

Financial news for PBMD dated on 2015-10-27: Prima Biomed Announces Belgian Regulatory Approval to Commence IIB Study of IMP321

Financial news for PBMD dated on 2015-10-19: Prima Biomed Big Volume Spike

Financial news for PBMD dated on 2015-10-14: Benzinga's Top Initiations

Financial news for PBMD dated on 2015-10-14: H.C. Wainwright Initiates Coverage on Prima Biomed at Buy, Announces \$3.00 PT

Financial news for PBMD dated on 2015-10-13: Prima Biomed +2.5% Premarket Following Announcement of A\$1.55M Investment from Nyenburg

Financial news for PBMD dated on 2015-10-13: UPDATE: Prima BioMed Raises A\$1.55M Through Private Placement to Nyenburgh Investment Partners @A\$0.05/Share

Financial news for PBMD dated on 2015-10-13: Prima Biomed Announces A\$1.55M Investment from Nyenburgh to be Used to Fund IMP321 Clinical Trial Program

Financial news for PBMD dated on 2015-10-09: UPDATE: Prima Biomed +40% Premarket Following Announcement of A\$475,000 in Grant Funding from EU, German Free State of Saxony

Financial news for PBMD dated on 2015-10-08: Prima Biomed Share Rise 20% After-Hours on News of Grant

Financial news for PBMD dated on 2015-10-08: UPDATE: Prima Biomed Receives A\$475,000 in Grant Funding from EU, German Free State of Saxony

Financial news for PBMD dated on 2015-10-08: Prima Biomed Receives A\$475,000 in Grant Funding from EU, German Free State of Saxony -Reuters

Financial news for PBMD dated on 2015-09-30: Prima Biomed Shares Move Higher; Co Curretly Presenting at LEERINK Partners Rare Disease Roundtable

Financial news for PBMD dated on 2015-08-14: Morning Market Gainers

Financial news for PBMD dated on 2015-08-14: Benzinga's Top #PreMarket Gainers

Financial news for PBMD dated on 2015-08-14: US Stock Futures Slip Ahead Of Economic Data

Financial news for PBMD dated on 2015-08-14: Prima Biomed Shares +50% Following Announcement of Milestone Payment from Novartis

Financial news for PBMD dated on 2015-08-14: Prima Biomed to Receive Undisclosed Milestone Payment from Novartis

Financial news for PBMD dated on 2015-08-04: Prima Biomed Terminates Investment Facility With Bergen Global Opportunity Fund

Financial news for PBMD dated on 2015-07-24: Prima BioMed Raises A\$10M Through Share Purchase Plan; Proceeds to be Used to Fund IMP321 Clinical Trial Program

Financial news for PBMD dated on 2015-07-08: Tuesday, Wednesday's Economic Conditions And Major Market Movers: China Continues To Decline, Greece Continues Delay

Financial news for PBMD dated on 2015-07-08: Morning Market Losers

Financial news for PBMD dated on 2015-07-08: US Stock Futures Down; FOMC Minutes In Focus

Financial news for PBMD dated on 2015-07-08: Shares of Prima Biomed Fall 16% Premarket in US; Down 31% in Australia, Following Announcement of Share Purchase Plan

Financial news for PBMD dated on 2015-07-08: UPDATE: Prima BioMed Share Purchase Plan Allows Eligible Shareholders to Subscribe for Up to A\$15,000 Worth of New Shares at A\$0.05/Share

Financial news for PBMD dated on 2015-07-08: Prima Biomed Announces Share Purchase Plan

Financial news for PBMD dated on 2015-07-07: Morning Market Gainers

Financial news for PBMD dated on 2015-07-07: UPDATE: Prima Biomed Shares Rise 67% Premarket After Announcing Positive Scientific Advice from EMA for Lead Product IMP321

Financial news for PBMD dated on 2015-07-07: Prima Biomed Receives Positive Scientific Advice from EMA for Lead Product Development -Reuters

Financial news for PBMD dated on 2015-06-11: Prima BioMed Receive EUR226,055 Cash Rebate from French State Under the Credit d'Impot Recher -6-K

Financial news for PBMD dated on 2015-06-09: Benzinga's Top #PreMarket Losers

Financial news for PBMD dated on 2015-06-04: Morning Market Losers

Financial news for PBMD dated on 2015-06-04: Benzinga's Top #PreMarket Losers

Financial news for PBMD dated on 2015-06-03: Morning Market Gainers

Financial news for PBMD dated on 2015-06-03: Benzinga's Top #PreMarket Gainers

Financial news for PBMD dated on 2015-06-01: Morning Market Losers

Financial news for PBMD dated on 2015-05-29: Morning Market Gainers

Financial news for PBMD dated on 2015-05-29: Benzinga's Top #PreMarket Gainers

Financial news for PBMD dated on 2015-05-29: UPDATE: Prima has Filed Provisional Patent Application over Use of IMP321 in Combination with Immune Checkpoint Inhibitors

Financial news for PBMD dated on 2015-05-29: Prima BioMed Announces New IP For Its Lead IMP321 Development Program

Financial news for PBMD dated on 2015-05-28: Morning Market Losers

Financial news for PBMD dated on 2015-05-28: Benzinga's Top #PreMarket Losers

Financial news for PBMD dated on 2015-05-26: Morning Market Gainers

Financial news for PBMD dated on 2015-05-26: Prima BioMed Says CVac Shows Clear Trend for Overall Survival Benefit in Second Remission Ovarian Cancer in Phase II Study

Financial news for PBMD dated on 2015-05-22: Benzinga's Top #PreMarket Losers

Financial news for PBMD dated on 2015-05-21: Morning Market Losers

Financial news for PBMD dated on 2015-05-21: Benzinga's Top #PreMarket Losers

Financial news for PBMD dated on 2015-05-21: Prima Biomed Shares Fall 35% Premarket Following 269% Gain Wednesday

Financial news for PBMD dated on 2015-05-20: UPDATE: Prima Biomed Shares Now Up 175% Following Tuesday Report on Final CVac Data from Phase II CAN-003 Ovarian Cancer Clinical Trial

Financial news for PBMD dated on 2015-02-27: Prima Biomed Shares Move Higher; Being Mentioned as Car T-Cell Play

Financial news for PBMD dated on 2014-07-16: Morning Market Movers

Financial news for PBMD dated on 2014-07-09: Prima BioMed Names Marc Voigt as CFO

Financial news for PBMD dated on 2013-11-25: Morning Market Movers

Financial news for PBMD dated on 2013-10-02: Stocks Hitting 52-Week Lows

Financial news for PBMD dated on 2013-09-25: Stocks Hitting 52-Week Lows

Financial news for PBMD dated on 2013-09-18: Stocks Hitting 52-Week Lows

Financial news for PBMD dated on 2013-09-18: Morning Market Losers

Financial news for PBMD dated on 2013-08-14: Prima BioMed's "CANVAS" Clinical Trial Approved to Start in Korea

Financial news for PBMD dated on 2013-08-05: Benzinga's Top Pre-Market Losers

Financial news for PBMD dated on 2013-07-10: Morning Market Movers

Financial news for PBMD dated on 2013-04-10: Prima Biomed Halted on Circuit Breaker, Now Up 49%

Financial news for PBMD dated on 2013-04-09: Morning Market Movers

Financial news for PBMD dated on 2012-10-01: Morning Market Movers

Financial news for PBMD dated on 2012-09-18: Morning Market Movers

Financial news for PBMD dated on 2012-07-13: Circuit Breaker: Prima Biomed Ltd, Volatility Trading Pause

Financial news for PBMD dated on 2012-06-21: Morning Market Losers

Financial news for PBMD dated on 2012-06-04: Morning Market Losers

Financial news for PBMD dated on 2012-05-24: From Earlier: Prima BioMed CEO to Step Down

